CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 57 enrolled
Drug / intervention
ANG003drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06052293
NCT06052293Phase 1Completed
CompareCT.gov

A Phase 1 Open-Label, Multicenter Study to Assess the Safety and Efficacy of ANG003 in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

Anagram Therapeutics, Inc.·interventional·Posted Sep 25, 2023·Updated Apr 27, 2026

In Brief

A Phase 1 clinical trial evaluating ANG003 for Exocrine Pancreatic Insufficiency. Completed, enrolled 57 participants across 20 sites.

Detailed Summary

Randomized, parallel, active-treatment Phase 1 study of a single dose of orally administered ANG003 with a test meal in adult subjects with cystic fibrosis-related exocrine pancreatic insufficiency. The study's overall objectives are to evaluate the safety, tolerability and effect of four dose levels of ANG003.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsExocrine Pancreatic Insufficiency
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
202420252026
First PostedSep 25, 2023
Enrollment StartAug 25, 2023
Primary CompletionJul 8, 2024
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 2.8 years ago

Interventions

ANG003drug

To evaluate four possible combinations of lipase, protease and amylase.